AAPL 173.18 2.2918% MSFT 397.84 0.7343% GOOG 168.46 1.7455% GOOGL 166.62 1.6844% AMZN 184.72 3.1955% NVDA 858.11 3.3357% META 441.84 0.6034% TSLA 180.1 0.0611% TSM 136.23 0.956% LLY 755.91 -2.683% V 267.61 0.1085% AVGO 1238.3 -0.3669% JPM 191.66 -0.1042% UNH 492.97 1.8302% NVO 124.02 -4.0167% WMT 59.71 1.4613% LVMUY 164.94 0.5609% XOM 116.24 0.181% LVMHF 825.49 0.3843% MA 441.1 -0.2194%
Last update at 2024-05-02T20:11:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 7713.00M | 8098.00M | -6871.00000M | 4975.00M | 6010.00M |
| Minority interest | -18.00000M | -20.00000M | 20.00M | 21.00M | 27.00M |
| Net income | 6327.00M | 6994.00M | -8995.00000M | 3439.00M | 4952.00M |
| Selling general administrative | 7808.00M | 7688.00M | 7661.00M | 4871.00M | 4551.00M |
| Selling and marketing expenses | 7814.00M | 7690.00M | 7661.00M | 4871.00M | 4551.00M |
| Gross profit | 36022.00M | 36445.00M | 30745.00M | 18067.00M | 16014.00M |
| Reconciled depreciation | 9595.00M | 10023.00M | 10380.00M | 1746.00M | 637.00M |
| Ebit | 10328.00M | 10159.00M | 5128.00M | 5464.00M | 5434.00M |
| Ebitda | 19923.00M | 20182.00M | 14816.00M | 6599.00M | 6071.00M |
| Depreciation and amortization | 9595.00M | 10023.00M | 9688.00M | 1135.00M | 637.00M |
| Non operating income net other | -576.00000M | 720.00M | 2314.00M | -938.00000M | 850.00M |
| Operating income | 10328.00M | 10159.00M | 5128.00M | 5464.00M | 5118.00M |
| Other operating expenses | 37055.00M | 37848.00M | 40341.00M | 20232.00M | 17443.00M |
| Interest expense | 1232.00M | 1334.00M | 1420.00M | 656.00M | 183.00M |
| Tax provision | 1368.00M | 1084.00M | 2124.00M | 1515.00M | 1021.00M |
| Interest income | 1862.00M | 550.00M | 71.00M | 69.00M | 380.00M |
| Net interest income | -1232.00000M | -1334.00000M | -1420.00000M | -656.00000M | -183.00000M |
| Extraordinary items | - | - | - | 0.00000M | -56.00000M |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 1368.00M | 1084.00M | 2124.00M | 1515.00M | 1031.00M |
| Total revenue | 46159.00M | 46385.00M | 42518.00M | 26145.00M | 22561.00M |
| Total operating expenses | 26918.00M | 27908.00M | 28568.00M | 12154.00M | 10896.00M |
| Cost of revenue | 10137.00M | 9940.00M | 11773.00M | 8078.00M | 6547.00M |
| Total other income expense net | -2615.00000M | -2061.00000M | -11999.00000M | -489.00000M | 1075.00M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 6345.00M | 7014.00M | -8995.00000M | 6490.00M | 4947.00M |
| Net income applicable to common shares | 6327.00M | 6994.00M | -9015.00000M | 3439.00M | 4920.00M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 96820.00M | 109314.00M | 118481.00M | 129944.00M | 10659.00M |
| Intangible assets | 36355.00M | 42775.00M | 53243.00M | 63969.00M | 1091.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 1596.00M | 1290.00M | 1368.00M | 1983.00M | 1116.00M |
| Total liab | 65702.00M | 73308.00M | 80599.00M | 78246.00M | 7349.00M |
| Total stockholder equity | 31061.00M | 35946.00M | 37822.00M | 51598.00M | 14031.00M |
| Deferred long term liab | 2166.00M | 4501.00M | 5407.00M | 6454.00M | 468.00M |
| Other current liab | 13106.00M | 10109.00M | 10241.00M | 7888.00M | -2064.00000M |
| Common stock | 292.00M | 292.00M | 292.00M | 292.00M | 221.00M |
| Capital stock | 292.00M | 292.00M | 292.00M | 292.00M | 221.00M |
| Retained earnings | 25503.00M | 23820.00M | 21281.00M | 34474.00M | 34065.00M |
| Other liab | 7392.00M | 10961.00M | 12340.00M | 15882.00M | 4544.00M |
| Good will | 21149.00M | 20502.00M | 20547.00M | 22488.00M | 6538.00M |
| Other assets | 2877.00M | 3342.00M | 7328.00M | 4834.00M | 2165.00M |
| Cash | 9123.00M | 13979.00M | 14546.00M | 12346.00M | 6911.00M |
| Cash and equivalents | 9123.00M | 13979.00M | 14546.00M | 12346.00M | 6911.00M |
| Total current liabilities | 21890.00M | 21868.00M | 19080.00M | 18304.00M | 1703.00M |
| Current deferred revenue | 1344.00M | 3693.00M | 3622.00M | 4492.00M | 172.00M |
| Net debt | 31594.00M | 31617.00M | 37127.00M | 35192.00M | 438.00M |
| Short term debt | 4400.00M | 5117.00M | 2504.00M | 3479.00M | 1703.00M |
| Short long term debt | 4264.00M | 4948.00M | 2340.00M | 3346.00M | 1703.00M |
| Short long term debt total | 40717.00M | 45596.00M | 51673.00M | 47538.00M | 7349.00M |
| Other stockholder equity | 6547.00M | 13102.00M | 18088.00M | 18352.00M | -17493.00000M |
| Property plant equipment | 6255.00M | 6049.00M | 5886.00M | 6252.00M | 5027.00M |
| Total current assets | 27273.00M | 33262.00M | 30192.00M | 29354.00M | 8884.00M |
| Long term investments | 2187.00M | 2713.00M | 433.00M | 767.00M | 1775.00M |
| Net tangible assets | -25947.00000M | -28236.00000M | -35968.00000M | -34859.00000M | 6402.00M |
| Short term investments | 130.00M | 3242.00M | 1285.00M | 3047.00M | 1973.00M |
| Net receivables | 13937.00M | 12516.00M | 8501.00M | 7685.00M | 5965.00M |
| Long term debt | 35056.00M | 39605.00M | 48336.00M | 43387.00M | 5646.00M |
| Inventory | 2339.00M | 2095.00M | 2074.00M | 4293.00M | 1195.00M |
| Accounts payable | 3040.00M | 2949.00M | 2713.00M | 2445.00M | 1892.00M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | 57.00M | 60.00M | 60.00M | 100.00M | 96.00M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -1281.00000M | -1268.00000M | -1839.00000M | -1520.00000M | -2762.00000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 292.00M | 292.00M | 292.00M | 292.00M | 221.00M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | 25503.00M | 23820.00M | 21281.00M | 34474.00M | 34065.00M |
| Treasury stock | - | -31259.00000M | -26237.00000M | -25357.00000M | -19574.00000M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 1037.00M | 1655.00M | 2084.00M | 6604.00M | -14027.00000M |
| Deferred long term asset charges | - | - | - | 510.00M | 1371.00M |
| Non current assets total | 69547.00M | 76052.00M | 88289.00M | 100590.00M | 1775.00M |
| Capital lease obligations | 1397.00M | 1043.00M | 997.00M | 805.00M | - |
| Long term debt total | 35056.00M | 39605.00M | 48336.00M | 43387.00M | 5646.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 3037.00M | 1297.00M | 2108.00M | -152.00000M | 74.00M |
| Change to liabilities | -887.00000M | 45.00M | -2117.00000M | 1136.00M | 103.00M |
| Total cashflows from investing activities | -1062.00000M | -538.00000M | -10859.00000M | -9770.00000M | -874.00000M |
| Net borrowings | -5311.00000M | -6182.00000M | 3928.00M | 17653.00M | -548.00000M |
| Total cash from financing activities | -16962.00000M | -16224.00000M | -1151.00000M | 7621.00M | -3535.00000M |
| Change to operating activities | -183.00000M | 606.00M | 1074.00M | 702.00M | 634.00M |
| Net income | 6345.00M | 7014.00M | -8995.00000M | 3460.00M | 4947.00M |
| Change in cash | -4991.00000M | -657.00000M | 2153.00M | 5909.00M | 1490.00M |
| Begin period cash flow | 14316.00M | 14973.00M | 12820.00M | 6911.00M | 5421.00M |
| End period cash flow | 9325.00M | 14316.00M | 14973.00M | 12820.00M | 6911.00M |
| Total cash from operating activities | 13066.00M | 16207.00M | 14052.00M | 8067.00M | 5940.00M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 10276.00M | 10686.00M | 10380.00M | 1746.00M | 637.00M |
| Other cashflows from investing activities | -2981.00000M | -862.00000M | -12214.00000M | -8782.00000M | 3.00M |
| Dividends paid | 4634.00M | 4396.00M | 4075.00M | 2679.00M | 2613.00M |
| Change to inventory | -69.00000M | 13.00M | 2672.00M | 463.00M | -216.00000M |
| Change to account receivables | -663.00000M | -2117.00000M | -2951.00000M | 1659.00M | -267.00000M |
| Sale purchase of stock | -8001.00000M | -6287.00000M | -1546.00000M | -7300.00000M | -320.00000M |
| Other cashflows from financing activities | 7104.00M | 641.00M | 542.00M | -53.00000M | -54.00000M |
| Change to netincome | -1078.00000M | -748.00000M | -197.00000M | -62.00000M | 901.00M |
| Capital expenditures | 1118.00M | 973.00M | 753.00M | 836.00M | 951.00M |
| Change receivables | -663.00000M | -1054.00000M | -646.00000M | 752.00M | -429.00000M |
| Cash flows other operating | -858.00000M | 251.00M | 12955.00M | 572.00M | -3.00000M |
| Exchange rate changes | - | - | - | - | -41.00000M |
| Cash and cash equivalents changes | -4958.00000M | -555.00000M | 2042.00M | 5918.00M | 1490.00M |
| Change in working capital | -2229.00000M | -1253.00000M | 983.00M | 3065.00M | 176.00M |
| Stock based compensation | 457.00M | 583.00M | 779.00M | 441.00M | 221.00M |
| Other non cash items | 955.00M | 570.00M | 9922.00M | 279.00M | -127.00000M |
| Free cash flow | 11948.00M | 15234.00M | 13299.00M | 7231.00M | 4989.00M |
Sector: Healthcare Industry: Drug Manufacturers - General
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company |
-0.51 1.15% | 43.70 | 13.27 | 6.99 | 2.31 | 3.66 | 3.06 | 7.03 |
| LLY Eli Lilly and Company |
-20.84 2.68% | 755.91 | 103.14 | 46.73 | 16.88 | 48.24 | 17.43 | 69.11 |
| JNJ Johnson & Johnson |
-1.26 0.83% | 149.92 | 29.17 | 14.33 | 3.74 | 5.18 | 3.80 | 15.22 |
| ABBV AbbVie Inc |
-0.91 0.56% | 160.81 | 42.38 | 13.68 | 4.88 | 22.14 | 5.72 | 31.93 |
| MRK Merck & Company Inc |
-0.54 0.42% | 128.26 | 59.83 | 12.33 | 4.50 | 6.47 | 4.94 | 23.79 |
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
430 East 29th Street, New York, NY, United States, 10016
| Name | Title | Year Born |
|---|---|---|
| Dr. Giovanni Caforio M.D. | Chairman & CEO | 1965 |
| Mr. David V. Elkins | Exec. VP & CFO | 1968 |
| Ms. Sandra Leung Esq. | Exec. VP & Gen. Counsel | 1961 |
| Dr. Christopher S. Boerner | Exec. VP & Chief Commercialization Officer | 1971 |
| Mr. Rupert Vessey BCH, BM, DPHIL, M.A. | Exec. VP and Pres of Research & Early Devel. | 1965 |
| Mr. Greg Meyers | Exec. VP and Chief Digital & Technology Officer | 1973 |
| Mr. Timothy Power | VP & Head of Investor Relations | NA |
| Ms. Cari Gallman | Sr. VP & Chief Compliance and Ethics Officer | NA |
| Ms. Ann M. Powell Judge | Exec. VP & Chief HR Officer | 1966 |
| Mr. Jitendra Tyagi | Head of US Drug Makers - India | NA |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
US 
AU
UK
CA
NZ
Please wait processing your request...